Prednisone
Other / unclassified targets TNF via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | METICORTEN | — | 1955-02-21 | fda.gov ↗ |
Trials 652 · started per year
Also used as a comparator or background therapy in 1,335 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 010 trials | ||||||
| Phase 0 | NCT04469842 Background | Dec 2023 → Jun 2027 expected | transplant-related bronchiolitis obliterans | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 0 | NCT04139304 Background | May 2021 → Jul 2029 expected | plasmablastic lymphoma | AIDS Malignancy Consortium | Recruiting | No outcome recorded |
| Phase 0 | NCT04146207 Background | Apr 2020 → Sep 2024 | chronic graft versus host disease | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 0 | NCT03457025 Background | Aug 2019 → Jun 2020 | Bell's palsy | NYU Langone Health | Withdrawn | No outcome recorded |
| Phase 0 | NCT03511196 Background | Sep 2018 → Jun 2022 overdue | prostate adenocarcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02416674 Background | Mar 2015 → Feb 2025 | abdominal wall malformation | Brigham and Women's Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT01888952 Background | Jul 2013 → Jan 2015 | neoplasm of mature B-cells | Anand B. Karnad | Completed | No outcome recorded |
| Phase 0 | NCT01760226 Background | Jan 2013 → Aug 2016 | post-transplant lymphoproliferative disease, primary mediastinal large B-cell lymphoma | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 0 | NCT01380535 Background | Nov 2011 → Mar 2015 | chronic graft versus host disease | Mallinckrodt | Completed | No outcome recorded |
| Phase 0 | NCT00736450 Background | Jul 2008 → Oct 2012 | diffuse large B-cell lymphoma | University of Nebraska | Terminated | No outcome recorded |
| Phase 1128 trials | ||||||
| Phase 1 | NCT07714421 Background | Dec 2026 → Oct 2030 expected | high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma | Jonsson Comprehensive Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07649304 Background | Sep 2026 → Apr 2028 expected | high grade B-cell lymphoma, high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement, plasmablastic lymphoma, primary effusion lymphoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07444710 Background | Aug 2026 → Sep 2027 expected | mantle cell lymphoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07548606 Background | May → Jun 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT07339267 Background | Jan 2026 → Dec 2028 expected | prostate carcinoma | Astellas Pharma Global Development, Inc. | Recruiting | No outcome recorded |
| Show all 128 trials opens the full record — a long page | ||||||
| Phase 1/2137 trials | ||||||
| Phase 1/2 | NCT07175415 Background | Oct 2026 → Oct 2031 expected | T lymphoblastic leukemia/lymphoma, acute lymphoblastic leukemia | Princess Maxima Center for Pediatric Oncology | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07706959 Background | Jul 2026 → Jan 2028 expected | peripheral T-cell lymphoma, not otherwise specified | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07638787 Background | Jun 2026 → Sep 2027 expected | large B-cell lymphoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07519031 Comparator | Apr 2026 → Nov 2027 expected | vitiligo | Xijing Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07535710 Background | Mar 2026 → Dec 2027 expected | Sezary syndrome, primary cutaneous T-cell lymphoma | Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| Show all 137 trials opens the full record — a long page | ||||||
| Phase 2470 trials | ||||||
| Phase 2 | NCT07654426 Background | Oct 2026 → Dec 2030 expected | chemotherapy-induced toxicity, diffuse large B-cell lymphoma | Beth Israel Deaconess Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07715734 Background | Sep 2026 → Mar 2031 expected | skin squamous cell carcinoma | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07662928 Background | Sep 2026 → May 2031 expected | Burkitt lymphoma | AIDS Malignancy Consortium | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07676175 Background | Jul 2026 → Jan 2028 expected | peripheral T-cell lymphoma, not otherwise specified | BeBetter Med Inc | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07650240 Background | Jul 2026 → Dec 2030 expected | metastatic prostate carcinoma, prostate adenocarcinoma | Mayo Clinic | Not yet recruiting | No outcome recorded |
| Show all 470 trials opens the full record — a long page | ||||||
| Phase 2/346 trials | ||||||
| Phase 2/3 | NCT07712588 Background | Sep 2027 → Jan 2031 expected | diffuse large B-cell lymphoma | Dizal Pharmaceuticals | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07072585 Background | Aug 2026 → Sep 2035 expected | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | Children's Oncology Group | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07569081 Background | Aug 2026 → Dec 2028 expected | VEXAS syndrome | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07668895 Comparator | Jul 2026 → Jul 2027 expected | pulmonary sarcoidosis | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07634471 Background | Jun 2026 → Jul 2032 expected | follicular lymphoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07412470 Background | Mar 2026 → Aug 2029 expected | transplant rejection | Sanofi | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07068165 Comparator | Jul 2025 → Jul 2028 expected | immunoglobulin G4-related sclerosing disease | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03605654 Background | Dec 2024 → Sep 2026 | transplant rejection | Medeor Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT06452537 Background | Jul 2024 → Jan 2026 overdue | myelin oligodendrocyte glycoprotein antibody-associated disease | Tianjin Medical University General Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT03348670 Background | Aug 2023 → Nov 2026 expected | prostate cancer | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05267600 Background | Jun 2022 → Sep 2024 | bullous pemphigoid | argenx | Completed | No outcome recorded |
| Phase 2/3 | NCT05548738 Comparator | Apr 2022 → Nov 2023 | chronic pain syndrome | Alexandria University | Completed | No outcome recorded |
| Phase 2/3 | NCT04787744 Background | Jul 2021 → Sep 2026 expected | metastatic prostate carcinoma | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04799275 Background | May 2021 → Mar 2027 expected | T-cell/histiocyte rich large B cell lymphoma, diffuse large B-cell lymphoma activated B-cell type, diffuse large B-cell lymphoma germinal center B-cell type, diffuse large B-cell lymphoma with chronic inflammation +5 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05931744 Comparator | May 2021 → Feb 2023 | chronic rhinosinusitis | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 2/3 | NCT04206553 Background | Oct 2020 → Jul 2024 | bullous pemphigoid | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/3 | NCT03984448 Background | Oct 2019 → Apr 2028 expected | high grade B-cell lymphoma, high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT03804931 Background | Jan 2019 → Dec 2028 expected | ulcerative colitis | Guangzhou First People's Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03584516 Background | Jan 2019 → Nov 2023 | chronic graft versus host disease | Incyte Corporation | Terminated | No outcome recorded |
| Phase 2/3 | NCT03706365 Background | Nov 2018 → Jan 2024 overdue | prostate cancer | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT03295565 Background | May 2017 → Dec 2020 | metastatic neoplasm, metastatic prostate carcinoma | The Netherlands Cancer Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT03117751 Background | Mar 2017 → Sep 2026 expected | lymphoblastic leukemia, acute, with lymphomatous features | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02205762 Background | Nov 2016 → Jul 2026 overdue | Langerhans cell histiocytosis | North American Consortium for Histiocytosis | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02914054 Comparator | Oct 2016 → Sep 2017 | autoimmune thrombocytopenic purpura, glucocorticoid therapy, response to | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT02871869 Background | Sep 2016 → Sep 2018 | diffuse large B-cell lymphoma | Xinjiang Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02451774 Comparator | Jan 2015 → Dec 2019 | childhood acute lymphoblastic leukemia | Ramón Óscar González-Ramella, Ph.D | Unknown | No outcome recorded |
| Phase 2/3 | NCT01809444 Comparator | Nov 2012 → Jan 2016 | disease of orbital part of eye adnexa | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01646736 Background | Jul 2012 → Jul 2013 | lupus nephritis | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT01106833 Background | Apr 2010 → Feb 2017 | chronic graft versus host disease | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 2/3 | NCT00789997 Comparator | Nov 2008 → Aug 2011 | chronic obstructive pulmonary disease | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT00720109 Background | Jul 2008 → Dec 2014 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), acute lymphoblastic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2/3 | NCT00573157 Background | Dec 2007 → Apr 2009 | lupus nephritis | EMD Serono | Terminated | No outcome recorded |
| Phase 2/3 | NCT00430677 Background | Jun 2007 → Sep 2010 | systemic lupus erythematosus | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 2/3 | NCT00633919 Comparator | Jul 2006 → Dec 2008 | allergic disease | ALK-Abelló A/S | Completed | No outcome recorded |
| Phase 2/3 | NCT00306670 Background | Apr 2006 → Jan 2011 | hemophilia A | Georgetown University | Terminated | No outcome recorded |
| Phase 2/3 | NCT00137969 Background | May 2005 → Aug 2008 | systemic lupus erythematosus | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT00104299 Background | Jan 2005 → Dec 2008 | granulomatosis with polyangiitis, microscopic polyangiitis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/3 | NCT00362531 Background | Nov 2004 → Jan 2007 | idiopathic membranous glomerulonephritis, nephrotic syndrome | Peking University | Completed | No outcome recorded |
| Phase 2/3 | NCT00774202 Comparator | Nov 2003 → Feb 2008 | autoimmune thrombocytopenic purpura | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 2/3 | NCT00060385 Background | Mar 2003 → Aug 2004 | lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | No outcome recorded |
| Phase 2/3 | NCT00268567 Background | Oct 2002 → ? | lupus nephritis | Peking University | Completed | No outcome recorded |
| Phase 2/3 | NCT00147121 Comparator | Sep 2002 → Feb 2010 | B-cell non-Hodgkin lymphoma | Haruhiko Fukuda | Completed | No outcome recorded |
| Phase 2/3 | NCT00135967 Background | May 2002 → ? | idiopathic membranous glomerulonephritis | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2/3 | NCT00838214 Comparator | Mar 2001 → Dec 2008 | autoimmune hepatitis | Dr. Falk Pharma GmbH | Completed | No outcome recorded |
| Phase 2/3 | NCT00004071 Background | Aug 1999 → Sep 2007 | prostate cancer | Pfizer | Completed | No outcome recorded |
| Phase 2/3 | NCT00729768 Background | — | — | Genentech, Inc. | Withdrawn | No outcome recorded |
| Phase 3349 trials | ||||||
| Phase 3 | NCT07220187 Background | Aug 2026 → Oct 2035 expected | Richter transformation | SWOG Cancer Research Network | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06833411 Comparator | Jul 2026 → Aug 2030 expected | temporal arteritis | Insel Gruppe AG, University Hospital Bern | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07620574 Background | May 2026 → May 2030 expected | colorectal cancer, differentiated thyroid carcinoma, hepatocellular carcinoma, pancreatic neuroendocrine tumor +2 | Exelixis | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07365995 Comparator | Apr 2026 → Feb 2031 expected | prostate carcinoma | BioNTech SE | Recruiting | No outcome recorded |
| Phase 3 | NCT07311694 Comparator | Feb 2026 → Dec 2027 expected | castration-resistant prostate carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Show all 349 trials opens the full record — a long page | ||||||
| Phase 4127 trials | ||||||
| Phase 4 | NCT06364319 Background | Jul 2026 → Dec 2027 expected | chronic graft versus host disease | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07630896 Comparator | Jul 2026 → Dec 2027 expected | osteoarthritis | Columbia University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07426484 Background | Jul 2026 → Dec 2030 expected | skin squamous cell carcinoma | Dana-Farber Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07228052 Comparator | Jul → Dec 2026 expected | asthma | Montefiore Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07611214 Background | Apr 2026 → Mar 2029 expected | lupus nephritis | Aurinia Pharmaceuticals Inc. | Recruiting | No outcome recorded |
| Show all 127 trials opens the full record — a long page | ||||||
| Phase not applicable65 trials | ||||||
| — | NCT07454226 Background | May 2026 → Mar 2028 expected | acute lymphoblastic leukemia, phosphohydroxylysinuria | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| — | NCT07483658 Background | May 2026 → Dec 2029 expected | prostate cancer | CHU de Quebec-Universite Laval | Recruiting | No outcome recorded |
| — | NCT07493161 Background | Apr 2026 → Mar 2028 expected | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| — | NCT07495631 Background | Apr 2026 → Mar 2028 expected | adult acute lymphoblastic leukemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| — | NCT07518277 Background | Apr 2026 → Apr 2028 expected | autoimmune hemolytic anemia, warm type | Chen Miao | Not yet recruiting | No outcome recorded |
| — | NCT07431060 Background | Feb 2026 → Dec 2030 expected | multisystem langerhans cell histiocytosis | West China Second University Hospital | Recruiting | No outcome recorded |
| — | NCT07172685 Background | Jul 2025 → Jun 2026 overdue | prostate cancer | Qilu Hospital of Shandong University | Recruiting | No outcome recorded |
| — | NCT06789315 Comparator | Jan 2025 → Jan 2026 overdue | alcoholic hepatitis | Institute of Liver and Biliary Sciences, India | Not yet recruiting | No outcome recorded |
| — | NCT06654596 Comparator | Dec 2024 → Dec 2026 expected | IgA glomerulonephritis | Ruijin Hospital | Recruiting | No outcome recorded |
| — | NCT06479304 Background | Apr 2024 → Jan 2026 overdue | autoimmune thrombocytopenia | Yunfeng Cheng | Recruiting | No outcome recorded |
| — | NCT07112209 Background | Nov 2023 → Jun 2027 expected | metastatic prostate carcinoma | Zhujiang Hospital | Enrolling by invitation | No outcome recorded |
| — | NCT06663618 Background | Sep 2023 → Mar 2025 overdue | immunoglobulin G4-related sclerosing disease | Wen Zhang | Recruiting | No outcome recorded |
| — | NCT05782933 Comparator | Aug 2022 → Dec 2023 | idiopathic membranous glomerulonephritis | Beijing Friendship Hospital | Unknown | No outcome recorded |
| — | NCT05789017 Background | Jul 2022 → Dec 2024 | autoimmune disease | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| — | NCT05789030 Background | Jul 2022 → Apr 2026 overdue | autoimmune disease | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| — | NCT05177445 Background | Apr → Dec 2022 | anosmia | Respiralab | Unknown | No outcome recorded |
| — | NCT05129033 Comparator | Nov 2021 → Jun 2023 | allergic bronchopulmonary aspergillosis | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| — | NCT05040555 Background | Aug 2021 → Sep 2023 overdue | diffuse large B-cell lymphoma | Ou Bai, MD/PHD | Recruiting | No outcome recorded |
| — | NCT04882683 Background | Jun 2021 → Jun 2022 | ulcerative colitis | Shandong Qilu Stem Cells Engineering Co., Ltd. | Unknown | No outcome recorded |
| — | NCT07049172 Background | Jan 2021 → Dec 2023 | nephrotic syndrome of childhood - steroid sensitive | Wuhan Children's Hospital | Completed | No outcome recorded |
| — | NCT04569890 Comparator | Dec 2020 → Dec 2022 | pregnancy disorder, rheumatoid arthritis | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT04380818 Background | Jun 2020 → Sep 2021 | viral pneumonia | Grupo de Investigación Clínica en Oncología Radioterapia | Unknown | No outcome recorded |
| — | NCT04220398 Background | Jan 2020 → Dec 2022 | chemotherapy-induced toxicity, prostate carcinoma | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT03724903 Comparator | Apr 2019 → Apr 2023 | granulomatous mastitis | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Completed | No outcome recorded |
| — | NCT03864250 Comparator | Nov 2018 → Nov 2020 | idiopathic membranous glomerulonephritis | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| — | NCT03625219 Comparator | Jul 2018 → Mar 2020 | type IV hypersensitivity disease | Innovaderm Research Inc. | Completed | No outcome recorded |
| — | NCT03549663 Comparator | Jul 2018 → Oct 2020 | idiopathic membranous glomerulonephritis | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| — | NCT03715699 Background | Jul 2018 → Dec 2020 | autoimmune disease | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| — | NCT03492255 Comparator | Apr 2018 → Jul 2021 | systemic lupus erythematosus | University of Sao Paulo General Hospital | Terminated | No outcome recorded |
| — | NCT03039608 Comparator | Feb 2017 → Jul 2018 | — | Shanghai Zhongshan Hospital | Completed | No outcome recorded |
| — | NCT02981979 Comparator | Dec 2016 → May 2022 | Takayasu arteritis | Jiang lindi | Completed | No outcome recorded |
| — | NCT02954198 Comparator | Dec 2016 → Dec 2018 | immunodeficiency disease | Medical University of South Carolina | Completed | No outcome recorded |
| — | NCT03022123 Background | Nov 2016 → Nov 2017 | diffuse large B-cell lymphoma | Hebei Medical University Fourth Hospital | Unknown | No outcome recorded |
| — | NCT02712697 Background | Jun 2016 → Dec 2017 | IgA glomerulonephritis | Shanghai University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| — | NCT02426502 Background | Apr 2016 → Aug 2022 | end stage renal failure | University of British Columbia | Unknown | No outcome recorded |
| — | NCT02562924 Background | Nov 2015 → Dec 2017 | chronic rhinosinusitis | University of Vermont Medical Center | Completed | No outcome recorded |
| — | NCT02797717 Background | Nov 2015 → Dec 2022 overdue | classic Hodgkin lymphoma | GALIA AVRAHAMI | Recruiting | No outcome recorded |
| — | NCT03390387 Comparator | Nov 2015 → Nov 2020 | childhood acute lymphoblastic leukemia | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Unknown | No outcome recorded |
| — | NCT02927834 Comparator | Aug 2015 → Dec 2018 | sinusitis | Loma Linda University | Completed | No outcome recorded |
| — | NCT02386735 Comparator | Mar 2015 → Jul 2024 | chronic obstructive pulmonary disease | Prof. Dr. Jörg Leuppi | Terminated | No outcome recorded |
| — | NCT02208583 Comparator | Jun 2014 → Dec 2016 | hormone-resistant prostate carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| — | NCT01961843 Background | Jan 2014 → Apr 2023 | prostate cancer | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT01987076 Comparator | Oct 2013 → Oct 2015 | drug rash with eosinophilia and systemic symptoms | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| — | NCT01782859 Comparator | Oct 2012 → Jan 2014 | — | Hospital for Special Surgery, New York | Completed | No outcome recorded |
| — | NCT01671423 Comparator | Aug 2012 → Sep 2015 | cellulitis | Albert Einstein Healthcare Network | Completed | No outcome recorded |
| — | NCT03811366 Background | Jun 2011 → Jan 2017 | Vogt-Koyanagi-Harada disease, optic choroid disorder, vision disorder | University of Sao Paulo | Completed | No outcome recorded |
| — | NCT01269021 Comparator | Nov 2010 → Oct 2013 | IgA glomerulonephritis | Zhi-Hong Liu, M.D. | Completed | No outcome recorded |
| — | NCT01559675 Comparator | Sep 2010 → Apr 2012 | orthostatic hypotension | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| — | NCT01161459 Background | Jun 2010 → Apr 2012 | idiopathic membranous glomerulonephritis | Zhi-Hong Liu, M.D. | Completed | No outcome recorded |
| — | NCT01879514 Background | Jan 2010 → Dec 2013 | IgA glomerulonephritis | Shanghai University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| — | NCT00907452 Comparator | Jul 2009 → Dec 2010 | plasma cell myeloma | Intergroupe Francophone du Myelome | Completed | No outcome recorded |
| — | NCT00934791 Comparator | Feb 2009 → Dec 2012 | autosomal dominant polycystic liver disease | Mayo Clinic | Terminated | No outcome recorded |
| — | NCT00544219 Background | Sep 2007 → Sep 2012 | lymphoma | Swiss Cancer Institute | Completed | No outcome recorded |
| — | NCT00530179 Comparator | Jul 2007 → Feb 2014 | diffuse large B-cell lymphoma | AHS Cancer Control Alberta | Completed | No outcome recorded |
| — | NCT00388739 Background | Nov 2006 | asthma | Baylor College of Medicine | Withdrawn | No outcome recorded |
| — | NCT00350545 Background | Aug 2006 → May 2012 | chronic graft versus host disease | Stanford University | Completed | No outcome recorded |
| — | NCT00550992 Background | Jan 2006 → Dec 2020 | leukemia | Dutch Childhood Oncology Group | Unknown | No outcome recorded |
| — | NCT00518310 Comparator | May 2005 → Dec 2008 | idiopathic pulmonary fibrosis | Thorax National Institute | Unknown | No outcome recorded |
| — | NCT00110006 Background | Dec 2004 → ? | lymphoma | Case Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| — | NCT00049569 Background | Jan 2003 → Mar 2006 | T-cell childhood acute lymphocytic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| — | NCT00561106 Comparator | Dec 2002 → Dec 2003 | Bell's palsy | University of the Republic | Completed | No outcome recorded |
| — | NCT00016302 Background | Apr 2001 → Jul 2007 | T-cell childhood acute lymphocytic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| — | NCT00006055 Background | Mar 2000 → ? | Takayasu arteritis, autoimmune hemolytic anemia, autoimmune thrombocytopenic purpura, eosinophilic granulomatosis with polyangiitis +8 | Fairview University Medical Center | Unknown | No outcome recorded |
| — | NCT01686464 Comparator | Jun 1998 → Jan 2005 | Bell's palsy | Wenzhou Medical University | Completed | No outcome recorded |
| — | NCT00004436 Background | Jul 1993 → Jun 2000 | hemangioma | FDA Office of Orphan Products Development | Completed | No outcome recorded |
| Phase not stated3 trials | ||||||
| — | NCT01834209 Background | — | prostate neoplasm | Janssen Research & Development, LLC | No longer available | No outcome recorded |
| — | NCT05401214 Background | — | prostate carcinoma | Janssen Research & Development, LLC | Approved for marketing | No outcome recorded |
| — | NCT01217697 Background | — | prostate cancer, urinary system neoplasm | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Approved for marketing | No outcome recorded |
Press releases naming this drug 9 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-07-28 | AbbVie | Third Pivotal Phase 3 Study Shows RINVOQ™ (upadacitinib) Plus Topical Corticosteroids Improves Skin and Itch Symptoms in Atopic Dermatitis Patients abbvie.com ↗ |
| 2020-06-19 | Roche Global Development | Roche’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints roche.com ↗ |
| 2020-03-31 | Takeda | Takeda Receives Positive CHMP Opinion for ADCETRIS ® (brentuximab vedotin) in Combination with CHP (Cyclophosphamide, Doxorubicin and Prednisone) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma takeda.com ↗ |
| 2020-01-27 | Incyte Corporation | Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine incyte.com ↗ |
| 2019-08-23 | Incyte Corporation | Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis incyte.com ↗ |
| 2017-05-23 | Novartis Pharmaceuticals | Novartis' new analyses reinforce the potential of Ultibro® Breezhaler® for COPD patients historically treated with steroids novartis.com ↗ |
| 2016-11-12 | Roche Global Development | Phase III GiACTA study shows Roche’s Actemra/RoActemra is superior to steroids alone in maintaining steroid-free remission for people with giant cell arteritis roche.com ↗ |
| 2014-05-16 | Takeda | Orteronel Plus Prednisone Improved Progression Free Survival in Men With Chemotherapy-Naïve Metastatic Castration Resistant Prostate Cancer in Phase 3 Study takeda.com ↗ |
| 2014-04-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and OncoGenex Announce Top-Line Survival Results of Phase III SYNERGY Trial Evaluating Custirsen in Combination with First-line Docetaxel and Prednisone for Metastatic Castrate-Resistant Prostate Cancer tevapharm.com ↗ |
Evidence & citations 26 cited values
Every value below carries the sentence it was read from. 1,991 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | prednisone | “including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE...” NCT04486391 ↗1938“Consolidation 6-thioguanine 60 mg/m2/d, 1 to 43 po; prednisone 40 mg/m2/d, on days 1-28 orally; vincristine 1.5 mg/m2/d, days 1, 8, 15, 22; idarubicin 7 mg/m2/d, on days 1, 8,...” NCT06211452 ↗ “A Phase 3 Open Label Multicenter, Randomized Study to Compare the Efficacy and Safety of the Zevalin (Ibritumomab Tiuxetan) Therapeutic Regimen Following Cyclophosphamide,...” NCT00384111 ↗ “The patients will be given RCHOP (Rituximab 375mg/m2 ivgtt, D0, Cyclophosphamide 750mg/m2, ivgtt D1, doxorubicin 50mg/m2,ivgtt D1, Vincristine 1.4mg/m2（max 2mg）, ivgtt D1...” NCT04842318 ↗ “The purpose of this study is to assess whether a 5-day treatment with orally administered prednisone provides patient-relevant benefits by improving the cough-related QoL of...” NCT04232449 ↗ “Then, the steroid doses (oral prednisone or its equivalent) were to be decreased from 10 mg/m²/day orally (day 7-13), to 7.5 mg/m²/day orally (day 14-30), to 4 mg/m²/day orally...” NCT00149890 ↗ “Patients were randomly assigned in a 1:1 ratio to either replace prednisone with 20 mg/day of hydrocortisone for 3 months, then reduce to 10 mg/day for 3 months before...” PMID 39874233 ↗ Jan 2025 “The purpose of the study is to assess the efficacy of the association of Lenalidomide (Revlimid) and R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, vincristine and...” NCT01393756 ↗ “bleomycin 10 units/m\^2 IV on Day 8 etoposide 200 mg/m\^2 IV on Days 1, 2 and 3 doxorubicin 35 mg/m\^2 IV on Day 1 cyclophosphamide 1250 mg/m\^2 IV on Day 1 vincristine 1.4...” NCT01118026 ↗ “1. Prednisone 0.8-1.0 mg/kg/d, the dose was gradually reduced, and after 4 weeks, the dose was reduced by 5mg every two weeks, and then reduced to 10mg/d for 4-6 months after...” NCT04966884 ↗ “After enrollment and randomization, patients assigned to corticosteroid therapy will receive it as a single-bolus intravenous injection of dexamethasone 20 mg (day 1), followed...” NCT05809011 ↗ “Intrathecal administration of 2nd, 3rd, and 4th doses of methotrexate 15 mg and hydrocortisone 50mg on day 2 or 3 of 2nd, 3rd, and 4th cycles of immunochemotherapy with...” NCT03123718 ↗ “To determine the toxicity profile and tolerability of alemtuzumab (Campath) when administered in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone...” NCT00161590 ↗ “CHOP will be given 60-120 minutes following SQ administration of Alemtuzumab as follows: cyclophosphamide 750 mg/m2 IV on day 1, doxorubicin 50 mg/m2 IV on day 1, vincristine...” NCT00323323 ↗ “Standard of Care Therapy. Eligible patients should be on a maintenance regimen of immunosuppressive agents including tacrolimus, a second agent such as but not limited to MMF...” NCT03657342 ↗ “OBJECTIVE: To evaluate the efficacy of 4 cycles of vinblastine, Adriamycin (doxorubicin), methotrexate, and prednisone (VAMP) in patients with favorable-risk Hodgkin lymphoma...” PMID 22735430 ↗ Jun 2012 “Methylprednisolone sodium succinate 80 mg powder dissolved in 100 mL of sodium chloride solution (intravenous infusion, once daily) from the day of surgery to day 3, followed...” NCT07116811 ↗ “a) Cyclophosphamide: 750 mg/m2 i.v. drip, administered on D1; b) Doxorubicin: 50 mg/m2 i.v. drip (or Epirubicin: 70mg/m2 i.v. drip), administered on D1; c) Vincristine: 1.4...” NCT06961500 ↗ “Patients in the corticosteroid group were treated with intravenous pulsed-steroid therapy: methylprednisolone 500 mg daily intravenously for three consecutive days followed by...” NCT01621880 ↗ “standard doses of R-CHOP21 chemotherapy (375 mg/m(2) intravenous rituximab, 750 mg/m(2) intravenous cyclophosphamide, 50 mg/m(2) intravenous doxorubicin, and 1·4 mg/m(2)...” PMID 24831981 ↗ May 2014 “Eligible patients received intravenous rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1·4 mg/m2 (maximum 2 mg/m2), and oral prednisone...” PMID 34022150 ↗ May 2021 “Prednisone 40 to 80 mg once a day (OD) according to weight bands for 2 weeks, followed by 20 to 40 mg OD according to weight bands for 2 weeks, then 10 to 20 mg OD according to...” NCT04738812 ↗ “Patients will begin prednisone therapy at a dose selected by the investigator or the treating physician with oral prednisone 60mg or 1mg/kg (if weight less than 60kg) or...” NCT02169219 ↗ “Medium dose oral glucocorticosteroid (30mg/d prednisone or equivalent) will be given to the experimental dose group and high dose oral glucocorticosteroid (60mg/d prednisone or...” NCT05105347 ↗ “Once the patient has started the study treatment, the dose of corticosteroids will be tapered every 5 days (e.g., dexamethasone 2 mg or prednisone 15 mg per taper), as...” NCT02490878 ↗ “PL-doxorubicin 35-40 mg/m(2) and epirubicin 70 mg/m(2) were given in combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab (according to...” NCT03022123 ↗ “The purpose of the study is to determine the recommended dose (RD) of lenalidomide (Revlimid) when administered in association with R-CHOP (rituximab (R), cyclophosphamide,...” NCT00901615 ↗ “High dose CS of 0.8 mg per kilogram per day or maximum of 60 mg per day prednisone or prednisone equivalent, whichever is less will be administered for 4 Weeks and will be...” NCT00573157 ↗ “Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in...” NCT01389427 ↗ “The drugs to be administered are: prednisone 5 mg orally twice daily, abiraterone 1000 mg orally once daily, enzalutamide 160 mg orally once daily, and cabazitaxel intravenous...” NCT03110588 ↗ “short-course chemoimmunotherapy with cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (CHOP-R) followed by 90-Y ibritumomab tiuxetan (RIT) with extended...” PMID 18981007 ↗ Nov 2008 “Study on the Treatment of Double/Triple-hit Diffuse Large B-cell Lymphoma With Chidamide and Lisaftoclax in Combination With Vepesidil, Rituximab, Cyclophosphamide, Adriamycin,...” NCT07552324 ↗ “CHOP chemotherapy will be administered at standard doses: cyclophosphamide 750 mg/m2, adriamycine 50 mg/m2, vincristine 1.4mg/m2 (maximum total dose: 2mg) and prednisone 100mg...” NCT02042391 ↗ “Phase 1 and 2: Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose that is appropriate for the severity of disease as outlined per local treatment...” NCT03721965 ↗ “Stepwise reduction in the dose, and ultimate discontinuation of, all non-belatacept immunosuppression (mycophenolate, sirolimus, everolimus, prednisone) guided by monitoring of...” NCT04177095 ↗ “Patients in R-miniCHOP group will receive rituximab 375 mg/m² on day 1, cyclophosphamide 400 mg/m², doxorubicin 25 mg/m², and vincristine 1 mg on day 2, and prednisone 40 mg/m²...” NCT05179733 ↗ “Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks before 15mg per day, and tapered at 2.5-5mg per 2 weeks to equal to or less...” NCT04762810 ↗ “Methylprednisolone(Common brand names: Medrol) or prednisone 20-40mg, qd for two weeks, then temper the dose gradually, and then 20mg qd for maintenance (The total duration of...” NCT03724903 ↗ “Patients with a persistently positive interim-PET scan assigned to arm B1 will receive another six cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine,...” NCT00554164 ↗ “Corticosteroid Methylprednisolone 2 mg/kg/day was given for 3 days, and for responding patients, the dose of prednisone must be at least 0.25mg/kg/day prednisone (or...” NCT05921305 ↗ “with varied cycles, including Daunorubicin, Vincristine, Prednisone, Pegaspargase, Rituximab, Cytarabine, Mercaptopurine, Cyclophosphamide, Methotrexate, Doxorubicin,...” NCT04845035 ↗ “Two-hundred and forty patients with acute urticaria admitted to emergency department will be randomised in a 1:1 ratio to receive levocetirizine or an association of...” PMID 31439599 ↗ Aug 2019 “Used drugs are rituximab,cyclophosphamide, prednisone, dexamethasone, vincristine, methotrexate, iphosphamide, teniposide, etoposide, dexamethasone, cytarabine,adriamycin,...” NCT01290120 ↗ “After surgery, participants were assigned by block-randomization to receive either placebo or oral prednisone at a dose of 1 mg/kg/day followed by weekly stepwise tapering in...” PMID 33787345 ↗ Apr 2021 “A Pilot Study of Cyclophosphamide/Pegylated Liposomal Doxorubicin/Vincristine/Prednisone (CDOP) Plus Rituximab for Treatment of Elderly Patients With Previously Untreated...” NCT00120198 ↗ “The purpose of this study is to determine whether prednisone, methotrexate, and cyclophosphamide are effective in the treatment of rapidly progressive sensorineural hearing...” NCT00000361 ↗ “Abiraterone acetate (JanssenBiotech, Inc/Johnson \& Johnson) 1000 mg orally daily plus prednisone 5 mg orally twice daily will be administered continuously during the duration...” NCT01688492 ↗ “Oral prednisone \[or oral prednisolone\] 60 mg/day week 1, 40 mg/day Week 2, 30 mg/day Weeks 3 and 4, tapered by 5 mg/week Week 5 and beyond until liver enzymes return to...” NCT02991144 ↗ “Rituximab combined with Chemotherapy (Rituximab, Cyclophosphamide, doxorubicin, Vincristine, Prednisone, Ifosfamide, Gemcitabine, cisplatin, Carboplatin, Etoposide, MESNA,...” NCT07187960 ↗ “Prednisone 30 mg/day, supplemented with calcium and omeprazole, and Prednisone were slowly reduced to 10 mg/day after symptoms were relieved, and combined with 7.5 mg/week MTX therapy.” NCT05395949 ↗ “Day 1 of each cycle will consist of an infusion of rituximab followed by the initiation of a 96-hour continuous infusion of etoposide, doxorubicin, and vincristine and oral prednisone.” NCT00799136 ↗ “When a donor organ becomes available for transplant, the patient will receive three anti-rejection drugs-cyclosporine, mycophenolate mofetil and prednisone-to prevent organ rejection.” NCT00009009 ↗ “Prednisone arm: will receive oral Prednisone 1mg/kg with max of 30 mg twice daily starting 24 hours after the Dexamethasone dose given in emergency department for 8 additional doses.” NCT02780479 ↗ “Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) followed by idiotype vaccine and granulocyte-macrophage colony-stimulating factor (GM-CSF).” NCT00005780 ↗ “Prednisone 15 mg/d + monthly pulse cyclophosphamide 700 mg/m ² diminished to 600 mg/m ² in patients over 65 years or having a creatinine clearance lower than 30 ml/min for 12 months.” NCT01570764 ↗ “Patients in treatment group will receive 0.5g/d methylprednisolone intravenously for 3 consecutive days in the 1st-2nd-3rd month ,then oral prednisone 0.5mg/kg/d on alternate days.” NCT04833374 ↗ “Patients received 375 mg/m(2) rituximab, 400 mg/m(2) cyclophosphamide, 25 mg/m(2) doxorubicin, and 1 mg vincristine on day 1 of each cycle, and 40 mg/m(2) prednisone on days 1-5.” PMID 21482186 ↗ Apr 2011 “Immunosuppressive/immunomodulatory agents including but not limited to antimalarials (i.e. hydroxychloroquine), methotrexate, azathioprine and corticosteroids (i.e. prednisone)” NCT04809623 ↗ “Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.” NCT03139604 ↗ “Daily oral prednisone/prednisolone 2 mg/kg/d (maximum 60 mg/d) for 6 weeks followed by alternate day prednisone/prednisolone, 1.5 mg/kg (maximum of 50 mg), for other 6 weeks.” NCT05734794 ↗ “Patients will receive abiraterone acetate at 1,000 mg (four 250 mg tablets daily in the morning after an overnight fast) concurrently with prednisone(1) at 10 mg once daily.” NCT01842321 ↗ “Subject received cyclophosphamide 400mg intravenous drip every 2 weeks combined with oral Prednisone 10-15 mg/d （standard of care）through the 24 weeks double blind period.” NCT05300932 ↗ “After diagnosis of cGvHD patients will receive prednisone 1 mg/kg BW orally and everolimus (whole tablets or dispersible tablets) orally (targeted trough level 3-8 µg/l).” NCT01862965 ↗ “Tapered prednisone with cyclosporine or tacrolimus via oral administration, consistent with local institutional practice (corticosteroids and cyclosporine A/tacrolimus)” NCT01380535 ↗ “CEOP, cyclophosphamide 750 mg/m2, epirubicin 70 mg/m2, vincristine 1.4 mg/m2 [maximum 2 mg] on day 1, and prednisone 60 mg/m2 [maximum 100 mg] on days 1-5 every 21 days” PMID 32349779 ↗ Apr 2020 “Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is one of the most effective front-line therapies to treat indolent B-cell lymphoma.” PMID 21931035 ↗ Sep 2011 “Multi-agent chemotherapy including vincristine, prednisone, daunorubicin, cyclophosphamide, pegaspargase, cytarabine, 6-MP, MTX, and dexamethasone per protocol phases.” NCT07454226 ↗ “Patients will receive in addition to ciclosporine A and corticosteroids (prednisone) 1 mg/kg/day, Rituximab at 375 mg/m²/infusion once a week for 4 consecutive weeks.” NCT01135641 ↗ “Prednisone (or oral equivalent) was administrated to patients as before entering the study and as per center's standard practice, but at a dose of at least 5 mg/day.” NCT00284934 ↗ “Corticosteroids according to the schedule of reduction of prednisone (or equivalent prednisone dose only if prednisone is out of stock in the market) and Rivaroxaban” NCT06780462 ↗ “At Baseline, all participants switched to corticosteroids (CS) provided by the sponsor with the oral prednisone or prednisolone dose at 20, 30, 40, 50, or 60 mg QD.” NCT03725202 ↗ “Rituximab 375mg/m2 D1; cyclophosphamide 750mg/m2 D2; adriamycin 50 mg/m2 D2 vincristine 1.4mg/m(Max 2mg) D2; prednisone 100mg/d D2-6; Zanubrutinib 160 mg, bid D1-21” NCT06005870 ↗ “Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma” NCT00204659 ↗ “All men will also be treated with prednisone 5 mg by mouth twice daily while on abiraterone acetate in order to blunt its associated mineralocorticoid side effects” NCT05574712 ↗ “Intravenous administration: Rituximab 375 mg/m2, Cyclophosphamide 400 mg/m2, Doxorubicin 25 mg/m2, Vincristine 1 mg, and Oral administration: Prednisone 40 mg/m2” NCT07215585 ↗ “Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.” NCT02392286 ↗ “Methylprednisolone 500 mg iv will be given for 3 consecutive days at the start of month 1,3,5 and followed by prednisone 0.5mg/kg/d (max 40mg/d) for 27 days.” NCT06781944 ↗ “Patients who are considered medical candidates for doxorubicin should receive CHOP chemotherapy (Cyclophosphamide, doxorubicin, vincristine and prednisone).” NCT00193440 ↗ “Prednisone at a dose of 1-2 mg/kg/d (or an equivalent dose of methylprednisolone) is taken orally for 2-3 weeks, and then the dosage is reduced regularly.” NCT07518277 ↗ “Participants will be uniformly treated with four drug-induction: vincristine (VCR), prednisone (PDN), pegylated asparaginase (PegASP), daunorubicin (DNR).” NCT07443592 ↗ “Patients received corticosteroids at months 1, 3, and 5 (methylprednisolone 0.5 g at days 1, 2, and 3, then prednisone 0.5 mg/kg/d from day-4 to day-30).” NCT05782933 ↗ “125 mg IV methylprednisolone immediately post-operatively x 3 doses q12hrs, then switching to oral prednisone at 1.0 mg/kg/day po divided into bid doses” NCT03292861 ↗ “Corticosteroids will be administered according to local practice, within a daily maintenance dosage range of 2.5 to15 mg for prednisone or prednisolone” NCT00452361 ↗ “standard of care combined with glucocorticoid(dexamethasone: 3mg qd x 5 days; or prednisone: 20mg qd x 5 days; or methylprednisolone: 16mg qd x 5 days)” NCT05855395 ↗ “Patients will be uniformly treated with four drug-induction: vincristine (VCR), prednisone (PDN), pegylated asparaginase (PegASP), daunorubicin (DNR).” NCT04179929 ↗ “VDCLP regimen (vincristine, daunorubicin, cyclophosphamide, L-asparaginase, and prednisone) combined with CM313 at the RP2D during induction therapy.” NCT07585734 ↗ “Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 15mg per day in 3 months.” NCT04762784 ↗ “Cyclophosphamide 750 mg/m2 IV, adriamycine 50 mg/m2 IV, vincristine 1.4mg/m2 IV, and prednisone 50mg/m2 PO every 3 weeks at days 50, 72, 94 and 116.” NCT01458548 ↗ “Prednisone 40 mg orally the day prior to the start of cemiplimab dosing (Cycle 1, Day 1) and then daily at tapering doses while receiving Cemiplimab” NCT04339062 ↗ “Brentuximab Vedotin, 1.8mg/kg/dose, d0、Rituximab, 375 mg/m2, d0、Cyclophosphamide, 750 mg/m2, d1、Doxorubicin, 50 mg/m2, d1、Prednisone, 60mg/m2, d1-5” NCT06925555 ↗ “Patients take prednisone by mouth on days 1 to 5 and etoposide, doxorubicin, and vincristine as a 96-hour infusion through a vein over days 1 to 5.” NCT00114738 ↗ “All enrolled subjects will be prescribed a 14-day course of corticosteroid therapy in the form of Prednisone 20 mg to be taken once daily by mouth.” NCT06588348 ↗ “Dose Adjusted - Etoposide Prednisone Vincristine Cyclophosphamide Doxorubicin - Rituximab (DA-EPOCH-R) and nivolumab are both feasible treatments.” NCT03620578 ↗ “Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116.” NCT00590447 ↗ “Bevacizumab 5mg / kg, once every two weeks, a total of 6 weeks of 4 courses, sequential prednisone 10mg / d orally, the total course of 12 weeks.” NCT04553510 ↗ “Patients in Group I are treated with prednisone (≤20 mg qd, or equivalent glucocorticoid, taper to ≤5mg in 3 months) and iguratimod (25 mg bid).” NCT05789030 ↗ “Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma” NCT00126243 ↗ “Recipients of abdominal wall transplants will need to receive global immunosuppression with tacrolimus, mycophenolate mofetil and prednisone.” NCT02416674 ↗ “Cyclophosphamide750mg/m2 IV, Doxorubicin 50mg/m2 IV, Vincristine 1.4mg/m2 (max 2mg) IV, Prednisone 100mg PO daily x 5 days Rituximab 375mg/m2” NCT00574730 ↗ “The subject's standard care regimen upon entering the study; this could consist of hydrocortisone, dexamethasone, prednisone or prednisolone.” NCT03532022 ↗ “Prednisone (or equivalent) at the time of the onset of clinical symptoms consistent with GI and/or liver aGVHD, as per the standard of care.” NCT02406651 ↗ “Prednisone: 0.8 mg/kg/d (maximum dose: 60 mg/d), reduced by 5 mg every 14 days, by 2.5 mg every 2 weeks after 30 mg/d until discontinuation.” NCT04047576 ↗ “Steroids-methylprednisolone/prednisone dosing will be given according to the local center standard of practice early post transplantation.” NCT03644667 ↗ “All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle.” NCT00327340 ↗ “Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4 and Prednisone, 60 mg/m2 oral, days 1 to 4” NCT00652041 ↗ “One gm of methylprednisolone i.v., on day 0, followed by 40 mg/day i.v. on days 1-4, and days 6-12 (or the p.o. prednisone equivalent).” NCT01524068 ↗ “The ARPI drugs used in this study will be either abiraterone acetate (Zytiga) (plus prednisone/prednisolone) or enzalutamide (Xtandi).” NCT04597125 ↗ “The choice of prednisone and azithromycin combined with or without MSCs was based on patient preferences (MSC n = 49, non-MSC n = 32).” PMID 31668569 ↗ Oct 2019 “Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) plus rituximab and campath every 3 weeks for up to 6 cycles” NCT01030900 ↗ “Drug: Prednisone Prednisone will be administered at a dose of 40 mg/m\^2 orally on Days 1-5 of Cycle 1-6, during induction treatment.” NCT04023916 ↗ “Methylprednisolone (solumedrol) and prednisone are a group of medications called steroids that may be helpful for painful episodes.” NCT00263562 ↗ “Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) + Alemtuzumab (Campath) every 3 weeks for up to 6 cycles.” NCT00069238 ↗ “Patients on both arms receive pre-treatment with prednisone oral before 6 cycles of 21 days each of immunochemotherapy with RCHOP” NCT04442412 ↗ “Yangzhengxiaoji capsule combined with CHOP regimen(Yangzhengxiaoji capsule,Cyclophosphamide,Vincristine,Doxorubicin,Prednisone)” NCT01949818 ↗ “Prednisone 40mg orally twice daily for 11 days, followed by 40mg once daily for 5 days, followed by 20mg once daily for 5 days” NCT00636935 ↗ “NSAIDS (Ibuprofen or Aspirin) or Glucocorticoid (Prednisone) therapy for 3 weeks with addional colchicine therapy for 3 months” NCT04323280 ↗ “Docetaxel 75 mg/m2 intravenous (iv) infusion every 3 weeks plus oral prednisone 5 mg twice daily for a maximum of 10 cycles.” NCT04139772 ↗ “Participants were randomized 1:1 to the IV methylprednisolone sodium succinate (1000-mg) or oral prednisone (1250-mg) group.” PMID 29507942 ↗ Jun 2018 “the baseline dose of prednisone or equivalent was to be kept unchanged for all treatment groups for the total study duration” NCT00377962 ↗ “Induction therapy: Prednisone 30mg/d, lasting for 4 weeks, then decreasing by 5mg/d every 2 weeks until maintained at 5mg/d” NCT06468709 ↗ “chronic oral corticosteroids, defined as a minimum dose of oral prednisone of 2 to 40 mg/day or 5 to 80 mg every other day.” NCT01125748 ↗ “Abiraterone acetate (1000 mg po QD) was administered in combination with prednisone (5 mg po BID) for a total of 26 weeks.” NCT01487863 ↗ “short-course etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin with dose-dense rituximab (SC-EPOCH-RR)” PMID 20130244 ↗ Feb 2010 “During Cycle 1, participants will receive prednisone, vincristine, pegaspargase/calaspargase pegol-mknL, and daunorubicin.” NCT05326516 ↗ “HLX01 plus cyclophosphamide, doxorubicin, vincristine, and prednisone (H-CHOP) and reference rituximab plus CHOP (R-CHOP)” PMID 32299513 ↗ Apr 2020 “conventional chemotherapy (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone) and rituximab (R-CHOEP-14)” PMID 23168367 ↗ Nov 2012 “R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 8 cycles” NCT01865110 ↗ “diclofenac 50 mg twice a day, prednisone 5mg once daily, methotrexate 10mg once weekly or sulfasalazine 500 twice daily” NCT06594822 ↗ “followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7” NCT01002339 ↗ “Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1, Vincristina: 1,4 mg/mq day 1 Prednisone: 40 mg/mq day 1-5,” NCT00774826 ↗ “concurrent low-dose glucocorticoid (such as prednisone 5 mg tablet twice daily/prednisolone 0.5 mg tablet once daily).” NCT00474383 ↗ “Assigned Interventions Sirolimus (Rapamune) Tacrolimus (Prograft) Prednisone (Deltasone, Prednicot, Rayos, Sterapred)” NCT04415476 ↗ “Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.” NCT00154284 ↗ “Prednisone: A corticosteroid drug with anti-inflammatory, anti-allergic, immunosuppressive, and anti-cancer effects.” NCT06829771 ↗ “corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.” NCT06729593 ↗ “corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.” NCT06729606 ↗ “Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred” NCT04976465 ↗ “Endostar 7.5mg/m2, for iv for continuous 14 days cyclophosphamide, pirarubicin, vincristine, teniposide, prednisone” NCT01430013 ↗ “corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.” NCT04843761 ↗ “Abiraterone acetate 1000 mg orally daily (supplied as four 250 mg tablets) and prednisone 5 mg orally twice daily” NCT01735396 ↗ “Patients with pelvic nodal disease may receive abiraterone and prednisone for 24 months as per STAMPEDE protocol.” NCT07483658 ↗ “Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)” NCT03696186 ↗ “prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for 12 cycles (28 days/cycle).” NCT00600535 ↗ “switch to oral prednisone at 1 mg/kg/day, tapered by 5 mg weekly until a maintenance dose of 10 mg/day is reached” NCT07420296 ↗ “treatment with either prednisone or dexamethasone as palliative therapy for the control of neurological symptoms” NCT04461418 ↗ “IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement” NCT05658640 ↗ “IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement” NCT05740449 ↗ “IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement” NCT05745714 ↗ “IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement” NCT05751044 ↗ “IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement” NCT07175415 ↗ “cyclophosphamide 750 mg/m2, hydroxydoxorubicin IV 50 mg/m2, vincristine IV 1.4 mg/m2 and prednisone 100 mg daily” NCT04745832 ↗ “Induction regimen:Patients will start induction treatment with association of Lenalidomide and Prednisone (RP).” NCT01160107 ↗ “Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone” NCT07608978 ↗ “Dose and schedule finding of AZD8186 added to approved labelled dose of abiraterone acetate (with prednisone).” NCT01884285 ↗ “Docetaxel can be administered in combination with prednisone/prednisolone at the discretion of the researcher.” NCT07503379 ↗ “1mL prednisone (MSD) + 2mL sodium hyaluronate (biochemical Industry Co., Ltd.) was injected under arthroscopy” NCT05603468 ↗ “standard of care plus abiraterone (oral 1000 mg abiraterone once daily plus oral 5 mg prednisone twice daily)” PMID 35405085 ↗ Apr 2022 “Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.” NCT01845792 ↗ “prednisone or prednisolone orally for at least one year post-transplantation with the following minimal doses” NCT01541176 ↗ “or a bioequivalent dose of oral corticosteroids (e.g., 1,250mg prednisone daily or 176mg dexamethasone daily)” NCT07100990 ↗ “burst dose of steroids (4 days of prednisone, 1mg/kg/dose to a maximum of 40 mg/dose to be given twice a day)” NCT00388739 ↗ “CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 6 cycles.” NCT01796002 ↗ “Pola-R-CHP is a combination of rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin” NCT06743945 ↗ “either oral prednisone alone, 1·0 or 1·5 mg/kg per day tapered over 12 or 18 months (prednisone alone group)” PMID 28342637 ↗ Mar 2017 “IV methylprednisolone prior to first 3 doses of study drug; oral prednisone tapered to 5-10 mg over 6 months” NCT01154387 ↗ “Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).” NCT02656615 ↗ “dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (DA-EPOCH-R)” PMID 32453640 ↗ May 2020 “prednisone withdrawal, with maintenance mycophenolate mofetil therapy and either cyclosporine or tacrolimus” NCT00214279 ↗ “bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc)” NCT01652261 ↗ “prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days” NCT00063817 ↗ “infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (EPOCH-R)” PMID 24224624 ↗ Nov 2013 “ZYTIGA - abiraterone acetate tablet, film coated plus prednisone tablet plus BICALUTAMIDE tablet for Oral” NCT03348670 ↗ “and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.” NCT02328222 ↗ “CHOP regimen includes the administrations of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.” NCT07496229 ↗ “One dose of Dexamethasone (20mg/day) followed by prednisone 1mg/kg/day with a maximum dose of 60mg/day.” NCT00953303 ↗ “Use of stable doses of oral corticosteroids was permitted (≤ 10 mg of prednisone or equivalent per day)” NCT00443651 ↗ “prednisone 25 mg , 2 tablets after breakfast for 5 days, one tablet for 3 days, half tablet for 2 days” NCT04410536 ↗ “CHOP chemotherapy: cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone; 6 or 8 cycles” NCT01649856 ↗ “maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone.” NCT01275274 ↗ “PO GC arm: Prednisone 15 mg/day for a week, reducing by 5 mg/day every 7 days until tapered fully off” NCT07245732 ↗ “followed by oral prednisone (starting dose 50 mg tapered until complete discontinuation in 4 months).” NCT06680349 ↗ “prednisolone/prednisone 5 mg taken orally twice daily or dexamethasone 0.5 mg taken orally once daily” NCT01664728 ↗ “A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma” NCT00686335 ↗ “Steroid taper will include prednisone doses equivalent to =\< 5 mg/day in all Arms through Week 104.” NCT03312907 ↗ “≤10 mg/day prednisone p.o., or equivalent corticosteroid, or NSAIDs p.o. from Day 1 through Week 24” NCT00462345 ↗ “Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.” NCT00461747 ↗ “prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years” NCT00323960 ↗ “Cyclophosphamide (Cy) + Doxorubicin (ADM) + Vincristine (VDS) + Prednisone (Pred) ]± Rituximab (R)” NCT06520163 ↗ “The initial dose of prednisone will be 0.5 mg/kg/day for 4 weeks, then 0.25 mg/kg/day for 8 weeks.” NCT00518310 ↗ “ADT with an ARSI (i.e. abiraterone + prednisone, or apalutamide, or enzalutamide) ± radiotherapyª” NCT06496581 ↗ “Mitoxantrone Hydrochloride Liposome with Cyclophosphamide, Vincristine, Etoposide and Prednisone” NCT06433362 ↗ “Prednisone will be initiated at a daily dose of 60 mg as concomitant therapy with inebilizumab.” NCT07132398 ↗ “Triple intrathecal therapy (Methotrexate/Cytarabine/Prednisone; days 0/1, 8, 15, 22, 29 and 36)” NCT03390387 ↗ “Modified Release Prednisone (Lodotra®) Compared to Immediate Release Prednisone (Prednisone IR)” NCT01821040 ↗ “oral prednisone (prednisone acetate, 0.3 mg/kg/day) is added to the above stable-stage regimen.” NCT07307534 ↗ “Abiraterone acetate (three dose levels in phase I) + prednisone (10mg/day)+LHRH + Radiotherapy” NCT01780220 ↗ “Prednisone was started at 0.7 mg/kg/day and then tapered according to a standardized protocol.” PMID 30054122 ↗ Jul 2018 “Prednisone 100mg PO - On Day 1 Prednisone will be administered after chemotherapy part of CHOP” NCT01839097 ↗ “Chidamide 30mg ，twice a week Prednisone 20mg qd Cyclophosphamide 50mg qd Thalidomide 100mg qd” NCT02879526 ↗ “Simultaneously, take orally 1000 mg of Abiraterone tablets and 5 mg of prednisone once a day.” NCT06134271 ↗ “The oral starting dose is prednisone 0.5 mg/kg/day (or equivalent), not exceeding 40 mg/day.” NCT07340463 ↗ “P (Prednisone): 60 mg/m²/day (max 100 mg/day) or equivalent dexamethasone dose on days 1-14.” NCT06930105 ↗ “R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (or prednisolone))” NCT02054559 ↗ “The initial dose of prednisone/prednisolone was 0.5-1 mg/kg/d (the maximum dose was 70 mg/d)” NCT05532111 ↗ “Prednisone or equivalent 1 mg/kg/d(up to 60 mg), gradually tapering to 7.5mg/d in 24 weeks.” NCT01646736 ↗ “Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim” NCT02142049 ↗ “Oral corticosteroids, equivalent to prednisone p.o, ≥ 5mg daily or ≥ 10mg on alternate days” NCT00284947 ↗ “Cyclophosphamide, Vincristine, and Prednisone (CVP) Followed by Iodine-131 Anti-B1 Antibody” NCT01663714 ↗ “Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone” NCT06072131 ↗ “Everolimus plus cyclosporine and prednisone will be used for maintenance immunosuppression” NCT00966836 ↗ “dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone” NCT05996185 ↗ “given prednisone for 1 mg / kg body weight × 7 days + somatosensory stimulation × 30 days” NCT04129983 ↗ “Chidamide Plus R-CHOP (Rituximab、Cyclophosphamide、Doxorubicin、Vincristine and Prednisone)” NCT06891157 ↗ “oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months” NCT00755859 ↗ “R-CHOP regimen, which includes cyclophosphamide, doxorubicin, vincristine and prednisone” NCT02012088 ↗ “oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day” NCT01930890 ↗ “Cyclophosphamide (750 mg/m\^2) + doxorubicin (50 mg/m\^2) + prednisone (100 mg days 2-6)” NCT06040320 ↗ “participants will be given prednisone 25 mg orally, once a day for 5 days post-surgery.” NCT07223580 ↗ “Efficacy of Lodotra®(Prednisone) in Reduction of Morning Stiffness Duration(K-IMPROvE)” NCT02072200 ↗ “methylprednisolone/prednisone on Day +7 to +28 followed by a taper if there is no GVHD” NCT00745420 ↗ “In phase II, participants will receive add-on oral prednisone (30mg/day) for one-week.” NCT06970080 ↗ “Vincristine, daunorubicin, cyclophosphamide, pegaspargase, prednisone, and venetoclax.” NCT07495631 ↗ “Prednisone or prednisolone per standard of care to obtain control of disease activity.” NCT04206553 ↗ “Prednisone 60 mg (p.o.) on day 1, followed by 20 mg/day on days 2-5, 7-14, and 16-19” NCT03286556 ↗ “followed by oral prednisone at 1 mg/kg/day with progressive decrease as usually done” NCT04239196 ↗ “Prednisone, 10 mg per oral, will be administered before the last dose of r-ATG (D6).” NCT02084446 ↗ “It is associated with prednisone 5 mg orally twice daily administered continuously.” NCT03230734 ↗ “Standardized treatment in the experimental arm will start at 0.5mg/kg/d prednisone.” NCT06342544 ↗ “both oral corticosteroids (prednisone 40mg) and olfactory training will be applied” NCT05177445 ↗ “and prednisone 100 mg/day PO on days 1-5 of every 21-day cycle for the first cycle” NCT05675813 ↗ “Prednisone, methylprednisolone or prednisonlone, once a day, orally administrated” NCT02936375 ↗ “Prednisone was administered at a dose of 100 mg orally on Days 1-5 of each cycle.” NCT00486759 ↗ “Patients take 40 mg of prednisone daily for 4 weeks to help reduce inflammation.” NCT07039019 ↗ “All patients received oral prednisone, tapered from 20 mg to 0 mg over 11 weeks.” PMID 35210264 ↗ Feb 2022 “treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus” NCT01517984 ↗ “Abiraterone Acetate: orally, 1000mg, qd, plus with prednisone orally, 5mg, bid.” NCT03356444 ↗ “Glucocorticoid taper (up to 52-week or 28-week of oral prednisone/prednisolone)” NCT03192969 ↗ “followed by oral administration of prednisone 30 mg per day on Days 4, 5, and 6” NCT04046549 ↗ “1 mg/kg of prednisone (or equivalent) each day until plasma exchange is stopped” NCT00799773 ↗ “A pre-phase therapy with Prednisone 100 mg p.o. is mandatory from d-4 until d0.” NCT03129828 ↗ “Prednisone - 100 mg, orally once daily for 5 days every 21 days for 2-6 cycles.” NCT03264131 ↗ “R-CHOP (Rituximab, Cyclophosphamide, doxorubicin, vincristine, and prednisone)” NCT00582725 ↗ “These patients will also be treated with prednisone 5 mg once daily with food.” NCT01751451 ↗ “Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)” NCT05051891 ↗ “Prednisone: the dose of prednisone was kept stable at 5 mg/day in the morning.” NCT01023815 ↗ “prednisone or prednisolone to manage alanine aminotransferase (ALT) elevation” NCT03517085 ↗ “prednisone 80 mg/m² orally or intravenously on d1-5, with two weeks intervals” NCT00869284 ↗ “Drug: Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle.” NCT05040906 ↗ “standard maintenance immunosuppression: tacrolimus, mycophenolate, prednisone” NCT06584773 ↗ “R-CHOP (Rituximab , Cyclophosphamide ,Doxorubicine ,Vincristine , Prednisone)” NCT02858258 ↗ “rituximab, cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone” NCT03293173 ↗ “2b) Severe exacerbation - Prednisone (oral): 40 mg once daily for 7-10 days” NCT02136875 ↗ “two standardized treatments called "mesalamine" (Pentasa®) and "prednisone"” NCT01536535 ↗ “Prednisone, 0.8mg/kg/d, taken orally or intravenously, for up to one month.” NCT06686927 ↗ “Prednisone 60 mg/m2 PO BID is administered daily on Days 1-5 of each cycle.” NCT04002947 ↗ “R-CHOP = Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone” NCT05058404 ↗ “Followed by prednisone 30 mg (day +6), 20 mg (day +7), and 10 mg (day +8).” NCT01066429 ↗ “Prednisone 10 day taper: 60mg for 5 days, then taper for five days to 0mg” NCT03457025 ↗ “A minimum dose of 5 mg prednisone, or equivalent, per day was maintained.” NCT01950819 ↗ “given 0.5 mg/kg IV or prednisone 0.5 mg/kg given by mouth on days 3 and 4” NCT00346151 ↗ “Abiraterone 1000mg oral, taken daily + Prednisone 5mg oral, 2 times a day” NCT03295565 ↗ “IVIg (1g/kg D1-D2) plus oral prednisone (1 mg/kg/day x 21 days (3 weeks))” NCT04968899 ↗ “R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,prednisone)” NCT03023878 ↗ “and Prednisone 30mg/m2 on Day1 through 5 of each 28-day treatment cycles” NCT03576378 ↗ “and prednisone orally (PO) three times daily every other day for 8 weeks” NCT00846742 ↗ “prednisone or prednisolone, alone or in combination with hydrocortisone” NCT02716818 ↗ “Prednisone 100 mg administered by oral on Day 1-5 of each 21-day cycle.” NCT05189197 ↗ “Prednisone or equivalent will be administered orally as Glucocorticoid.” NCT05379634 ↗ “post-induction therapy with cyclophosphamide + bortezomib + prednisone” NCT00570180 ↗ “Rituximab-CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone).” NCT00355199 ↗ “Prednisone (P) 40mg/m2/day PO divided in 2 doses every day on Day 1-7” NCT01858922 ↗ “glucocorticosteroid (prednisone, dexamethasone or methylprednisolone)” NCT02188368 ↗ “L-VAMP (leucovorin, vincristine, aracytin, methotrexate, prednisone)” NCT04475731 ↗ “Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone” NCT06549595 ↗ “Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)” NCT01998633 ↗ “glucocorticoid ( prednisone/prednisolone) 0.5mg/kg (maximum 40mg/d)” NCT06654596 ↗ “Prednisone 40 milligrams per square meter per day, orally, day 5-32” NCT02451774 ↗ “Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone” NCT06517511 ↗ “Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone” NCT06647940 ↗ “and Prednisone 20 mg by mouth or Naso-gastric tube (NGT) on day 6” NCT00296244 ↗ “then prednisone 1 mg/kg/day (not to exceed 60 mg/day) for 4 weeks” NCT01275287 ↗ “Glucocorticoids (prednisone or prednisolone) will be administered” NCT07569081 ↗ “Corticosteroids (Prednisone, or IV methylprednisolone equivalent)” NCT05123040 ↗ “Rituximab, Cyclophosphamide, doxorubicin, vincristine, prednisone” NCT03995147 ↗ “Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone” NCT07398638 ↗ “For patients in complete remission, Prednisone: 5mg；Oral tablets” NCT06079788 ↗ “Prednisone: 20mg QD during the cycle 1-6 (each cycle is 28 days)” NCT07195799 ↗ “CHOP : Cyclophosphamide, Doxorubicin, Vincristine, \& Prednisone” NCT02594267 ↗ “CHOP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone” NCT00974324 ↗ “60 mg/m2 twice daily by mouth from day 1 to day 5 for prednisone” PMID 37011643 ↗ Mar 2023 “prednisone (tablet), once methylprednisolone is no longer needed” NCT02137239 ↗ “Prednisone: 60 mg/m\^2 per day by mouth (PO) daily on days 1-5.” NCT02356159 ↗ “Methylprednisolone; Cyclophosphamide; Prednisone; Mycophenolate” NCT03917797 ↗ “Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles” NCT00268853 ↗ “15 mg / 12h of Prednisone during 5 days after the intervention” NCT06076824 ↗ “CHOP regimen(Cyclophosphamide,Vindesine,Epirubicin,Prednisone)” NCT03631862 ↗ “Prednisone 100mg D1-5, oral Zanubrutinib 160mg BID D1-21, oral” NCT06255704 ↗ “corticosteroid(equal dose to prednisone 0.75mg/kg/day,4 weeks)” NCT02056418 ↗ “Rituximab 375 mg/m2 IV weekly X 4 doses + Prednisone 1 mg/kg/d” NCT01066598 ↗ “prednisone 60 mg/m2 (maximum dose 100 mg) orally from day 1-5” PMID 31126528 ↗ Jun 2019 “* prednisone orally, 0.5 mg/kg on alternate days for 6 months” NCT00135954 ↗ “Corticosteroids (methylprednisolone/dexamethasone/prednisone)” NCT04380818 ↗ “Enzalutamide or Abiraterone Acetate + Prednisone/Prednisolone” NCT06764485 ↗ “Rituximab,Cyclophosphamide,Doxorubicin,Vincristine,Prednisone” NCT04058470 ↗ “Prednisone: 1 mg/kg/day, days 1-14; 0.5 mg/kg/day, days 15-28” NCT07059156 ↗ “followed by Prednisone 20 mg orally when oral diet is resumed” NCT01559675 ↗ “receive a dose of prednisone at 1 mg/kg (ATG premedication)” NCT06315309 ↗ “Prednisone/Prednisolone 4mg/kg/day (Max 120 mg/day) x 4 day” NCT03939637 ↗ “prednisone 30 mg orally tid from d1 to d5 in a 21-day cycle” NCT06890585 ↗ “cyclophosphamide. doxorubicin, vincristine , and prednisone” NCT04243434 ↗ “receive a dose of prednisone at 1 mg/kg (ATG premedication)” NCT06265584 ↗ “Prednisone 60 mg /m2 po daily on Days 1-7 of a 28-day cycle” NCT00691704 ↗ “corticosteroids,prednisone,methylpredisolone,hydrocortisone” NCT00842933 ↗ “plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5” NCT02268045 ↗ “Prednisone/Prednisolone (at the investigator's discretion)” NCT07172685 ↗ “Prednisone 2mg/kg/d (or methyl-prednisolone IV equivalent)” NCT02133924 ↗ “Cyclophosphamide, doxorubicin, vincristine, and prednisone” NCT02670317 ↗ “Patients will be maintained on the same prednisone dose.” NCT02426502 ↗ “prednisone 100mg/m2 PO from day +1 to day +5¸ Campath-1H” NCT01679860 ↗ “Vincristine + Prednisone + Olverembatinib (± Venetoclax)” NCT07493161 ↗ “Change of prednisone 5mg/12h to dexamethasone 0.5mg/24h” NCT02928432 ↗ “Prednisone 40 (20-60) mg/m2 PO daily or every other day” NCT00117598 ↗ “Participants were treated with 1 mg/kg prednisone daily” PMID 38555718 ↗ Mar 2024 “Drug: Prednisone Prednisone 100 mg administered orally” NCT03485118 ↗ “Cyclophosphamide, doxorubicin, vincristine, prednisone” NCT05963347 ↗ “cyclophosphamide, doxorubicin, vincristine, prednisone” NCT01459887 ↗ “Oral prednisone 5 mg will be administered twice daily.” NCT01400555 ↗ “Prednisone, Cyclophosphamide, Etoposide, Procarbazine” NCT00151281 ↗ “postoperative prednisone 30 mg daily × 7 days; n = 18” PMID 24482348 ↗ Jan 2014 “Prednisone: 100 mg, po, day 2 to day 6 of each cycle” NCT02772822 ↗ “Prednisone: 100 mg, po, day 2 to day 6 of each cycle” NCT03650933 ↗ “Prednisone: 100 mg, po, day 2 to day 6 of each cycle” NCT02867566 ↗ “in a regimen wih low doses tacrolimus and prednisone” NCT02671318 ↗ “Prednisone 100 mg/d from day 1 to 5 and every 14 d.” NCT00849355 ↗ “Prednisone: 60 mg/m2 given orally bid on days 1-5.” NCT04992377 ↗ “Day 3: prednisone, 100 mg, given orally once daily” NCT00035555 ↗ “Asciminib, Dasatinib, Prednisone, and Methotrexate” NCT06773936 ↗ “* Steroids: prednisolone 1.5 mg, prednisone 0.5 mg” NCT01734759 ↗ “Prednisone, 60mg/ m2 , d1-d5,oral administration.” NCT06412068 ↗ “Prednisone: 50 mg alternating days during 2 years” NCT00560053 ↗ “Glucocorticoids 0.5-1mg/kg every day(prednisone)” NCT01642979 ↗ “plus oral corticosteroid ( prednisone 40 mg/day)” NCT01089322 ↗ “Tripterygium wilfordii 120mg/d Prednisone 30mg/d” NCT01161459 ↗ “Prednisone Acetate Tablets 1-1.5mg/kg/d d1-10 po” NCT04026269 ↗ “5 mg prednisone administered orally twice daily” NCT03587285 ↗ “Glucocorticoids0.25 mg/kg every day(prednisone)” NCT01760096 ↗ “Prednisone 100 mg oral Days 8-12 of each Cycle” NCT01139359 ↗ “Drug: Oral Prednisone - Hospital Dose Steroids” NCT07258771 ↗ “plus low dose steroids (prednisone, 10 mg/day)” NCT01346085 ↗ “Prednisone, PO daily on days 1, 2, 3, 4, and 5” NCT02700022 ↗ “Prednisone 60 mg/m2/d (divided bid) PO day 1-5” NCT00187161 ↗ “Prednisone, which will be taken by mouth daily” NCT00942578 ↗ “Prednisone tapering doses given orally daily:” NCT05470491 ↗ “prednisone ,40 mg/m² PO day1\~5 every 3 weeks” NCT02445404 ↗ “Prednisone, 40 mg/m2 po, days 1-5, cycles 1-6” NCT04332822 ↗ “prednisone(P) 60 mg/m2 orally on days 1 to 5” NCT01788137 ↗ “prednisone, prednisolone, methylprednisolone” NCT06388564 ↗ “prednisone, methylprednisolone, prednisolone” NCT06585774 ↗ “high dose of oral prednisone (1.0 mg/kg/day)” NCT03811366 ↗ “oral prednisone (2 mg/kg/day, max 60mg/day)” NCT07049172 ↗ “* Prednisone 100 mg i.v or oral. days 1-5.” NCT00466258 ↗ “Prednisone100 mg orally from days +1 to +5” NCT02223208 ↗ “Prednisone: 100 mg, Days 2-6 of each cycle” NCT07499271 ↗ “prednisone 50mg PO days 1\~5 twice per day” NCT00854568 ↗ “vindesine 4mg d1, prednisone: 100mg, d1-5.” NCT06674096 ↗ “prednisone 50mg PO days 1-5 twice per day” NCT01914718 ↗ “Prednisone tablet: 40mg/m2, po, day 1\~14” NCT02800447 ↗ “prednisone 50mg PO days 1-5 twice per day” NCT01804127 ↗ “prednisone (60 mg/m2 orally on days 1-5)” NCT06739265 ↗ “Methotrexate/Cytarabine/Prednisone i.th.” NCT01953770 ↗ “followed by oral prednisone for 6 months” NCT06510114 ↗ “Prednisone: 100 mg/day, orally, Days 2-6” NCT07680933 ↗ “Prednisone PO (60 mg/m²/day)day1 to day5” NCT00863460 ↗ “Prednisone 60 mg/m2/bid oral or IV d1-d5” NCT01818908 ↗ “PREDNISONE Dosage: 60 mg/m2, IV, day 1-5” NCT01361191 ↗ “Prednisone 5 mg orally twice daily (bid)” NCT07311694 ↗ “Prednisone 60mg/m2 （max 100mg）,PO,D1-D5” NCT04480099 ↗ “From D1 to D5 : Prednisone 60 mg/m² PO.” NCT03931642 ↗ “Prednisone 60mg/m2 （max 100mg）,PO,D1-D5” NCT05018520 ↗ “Prednisone at 100mg from day 1 to day 5” NCT06290817 ↗ “prednisone tablets (40 mg/㎡ once daily” NCT06959732 ↗ “Drug:Prednisone Description:5mg,po,bid” NCT07112209 ↗ “Prednisone 40 mg/m2 orally day 1 to 14” NCT00433433 ↗ “CM313 (SC)、Glucocorticoid (Prednisone)” NCT06663943 ↗ “oral prednisone 40 mg/m(2) on days 1-5” PMID 26687958 ↗ Mar 2015 “prednisone 100 mg/m2/D from D1 to D5.” NCT00970385 ↗ “40 mg/m2 oral prednisone on days 1-14” PMID 30658935 ↗ Jan 2019 “Prednisone: 100 mg daily p.o. day 1-5” NCT00791947 ↗ “≤ 2.5 mg of prednisone or equivalent” NCT04124861 ↗ “prednisone 100 mg/m2 per day PO D2-6” NCT03318835 ↗ “prednisone 100 mg/m2 per day PO D2-6” NCT04164368 ↗ “oral prednisone 40 mg/m2 on days 1-5” NCT00440583 ↗ “Prednisone 100 mg/d p.o. days 1 to 5” NCT00064116 ↗ “Prednisone: 60 mg/m2 po on days 1-28” NCT02396043 ↗ “Prednisone-60 mg/m2: D1 D2 D3 D4 D5” NCT01285765 ↗ “Prednisone, 100 mg qd, po day 2-6.” NCT05428670 ↗ “Prednisone (100 mg/sm,D 1-5)/cycle” NCT00842114 ↗ “prednisone 40 mg PO daily x 4 days” NCT01742338 ↗ “or the P.O. prednisone equivalent” NCT01266317 ↗ “Prednisone 100mg orally, day 1-5.” NCT05075460 ↗ “Prednisone (P) 100mg orally d1-5” NCT06158399 ↗ “Prednisone: 100 mg PO days 3 - 7” NCT00401817 ↗ “Prednisone 60 mg/m², po Days 1-5” NCT07494565 ↗ “30 mg/day prednisone for 1 week” NCT06285617 ↗ “E) Prednisone: 40mg/m2, D1-5,po” NCT05572983 ↗ “Prednisone: 100 mg PO days 1-5” NCT03542266 ↗ “Prednisone: 100 mg day 1-5 os” NCT02063685 ↗ “Prednisone 100 mg at days 1-4” NCT01333605 ↗ “Prednisone: 60mg/m2, po, d1-5” NCT05093140 ↗ “* Prednisone 50 mg， bid D2-6” NCT05257018 ↗ “Prednisone: 100 mg, Days 1-5” NCT07677813 ↗ “Prednisone 100mg po days 1-5” NCT00530179 ↗ “Prednisone 100mg PO days 1-5” NCT07538180 ↗ “Prednisone: 100 mg, po, d1-5” NCT07059650 ↗ “oral prednisone 2 mg/kg/day” NCT05643638 ↗ “2 mg/kg prednisone on day 4” NCT00801632 ↗ “Prednisone ，30mg ，tid， D1-5” NCT05527912 ↗ “Drug: Prednisone Prednisone” NCT06486337 ↗ “Prednisone 60mg/m2,p.o,d1-5” NCT01664975 ↗ “Prednisone 100mg D1-5, oral” NCT04736914 ↗ “Prednisone: 60 mg/m2, d1-d5” NCT05896813 ↗ “Prednisone® /Prednisolone®” NCT05468320 ↗ “prednisone (or equivalent)” NCT07611214 ↗ “Prednisone 60mg/m２/d, d1-5” NCT04134247 ↗ “Prednisone 100 mg, day 1-4” NCT00636311 ↗ “Prednisone: 100mg po D1-5;” NCT05577364 ↗ “Prednisone 60mg/ m2, D1\~5” NCT05040555 ↗ “C : prednisone (CORTANCYL)” NCT02552251 ↗ “Prednisone 60mg/m2 1 to 5” NCT00504491 ↗ “Prednisone or equivalent:” NCT00617604 ↗ “prednisone, or equivalent” NCT00965094 ↗ “Dexamethasone, Prednisone” NCT02130817 ↗ “Prednisone 5mg BID orally” NCT04220398 ↗ “Prednisone (100 mg，d1-5)” NCT06569485 ↗ “Prednisone or equivalent” NCT06246513 ↗ “Prednisone or equivalent” NCT06952686 ↗ “prednisone 100 mg day1-5” NCT06347653 ↗ “oral prednisone 5mg bid.” NCT00663832 ↗ “Prednisone: 100 mg, d1-5” NCT05974085 ↗ “Prednisone 69 mg.m2 D2-6” NCT06750991 ↗ “Prednisone 60 mg/m2 D2-6” NCT06701357 ↗ “prednisone: 100 mg, D1-5” NCT06901999 ↗ “prednisone 100 mg/day PO” NCT07706959 ↗ “prednisone 60mg d1-5 po” NCT03513601 ↗ “prednisolone/prednisone” NCT05850546 ↗ “prednisone/prednisolone” NCT04876651 ↗ “prednisone: 100mg, d1-5” NCT05290090 ↗ “prednisone 100 mg D1-4” NCT05244642 ↗ “prednisone + sirolimus” NCT06981845 ↗ “Prednisone 100mg d1-5” NCT05164770 ↗ “prednisone 100mg d1-5” NCT04152577 ↗ “prednisone 0.6mg/kg/d” NCT02797665 ↗ “Prednisone 100mg d1-5” NCT05097443 ↗ “Prednisone, Entocort” NCT00109473 ↗ “prednisone, various” NCT01729494 ↗ “Prednisone orally” NCT06760039 ↗ “Prednisone taper” NCT03793439 ↗ “Drug: Prednisone” NCT04780464 ↗ “Pred：prednisone” NCT03201471 ↗ “prednisone” NCT00933231 ↗ “Prednisone” NCT06178146 ↗ “prednisone” NCT00135694 ↗ “Prednisone” NCT00706680 ↗ “Prednisone” NCT00592111 ↗ “Prednisone” NCT03895801 ↗ “prednisone” NCT04553003 ↗ “prednisone” NCT02872597 ↗ “Prednisone” NCT06697535 ↗ “Prednisone” NCT00132691 ↗ “Prednisone” NCT03752307 ↗ “Prednisone” NCT05197842 ↗ |
| Known as | Apo-Prednisone Cordorol | “Apo-Prednisone Cordorol, Detasone - Prednisone” NCT01903486 ↗ |
| Known as | Cortancyl | “patients were standardized to 5 mg and 1 mg tablets of immediate release prednisone (Cortancyl).” NCT00686335 ↗6“Cortancyl (prednisone) 0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week” NCT01407484 ↗ “Patients assigned to this group will receive Prednisone : Cortancyl 20mg.” NCT03128905 ↗ “C : prednisone (CORTANCYL)” NCT02552251 ↗ “Prednisone (Cortancyl®)” NCT02627417 ↗ “Cortancyl” NCT00545402 ↗ |
| Known as | Corticosteroids | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05669001 ↗ |
| Known as | Decortin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01092533 ↗ |
| Known as | Deltacortene | “Prednisone (Deltacortene) 25 mg /day will be orally administered from day 1 to day 28 only in cycle 1” NCT03161054 ↗ |
| Known as | deltacortene (prednisone) | “deltacortene (prednisone)” NCT00480272 ↗ |
| Known as | Detasone | “Apo-Prednisone Cordorol, Detasone - Prednisone” NCT01903486 ↗ |
| Known as | ESCALATED BEACOPP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00795613 ↗ |
| Known as | Glucocorticoid (GC) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07159906 ↗ |
| Known as | kenakort in orabase | “kenakort in orabase” NCT06060301 ↗ |
| Known as | Lodotra | “The purpose of the study is to compare the safety and efficacy, with regards to the signs and symptoms, of MR prednisone (Lodotra®) versus placebo in combination with standard...” NCT00650078 ↗3“A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma” NCT00686335 ↗ “Modified Release Prednisone (Lodotra®) Compared to Immediate Release Prednisone (Prednisone IR)” NCT01821040 ↗ “Efficacy of Lodotra®(Prednisone) in Reduction of Morning Stiffness Duration(K-IMPROvE)” NCT02072200 ↗ |
| Known as | medthylprednisolone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05548738 ↗ |
| Known as | metilprednisolone | “Initially, all patients undergo a cycle of three ultrasound-guided subacromial corticosteroid injections (metilprednisolone 40 mg) administered once weekly to reduce...” NCT07508969 ↗ |
| Known as | NSC-10023 | “Prednisone, PRED, NSC-10023” NCT00002499 ↗3“Prednisone, PRED, NSC-10023” NCT00002462 ↗ “PRED Prednisone, NSC-10023” NCT00002599 ↗ “PRED Prednisone, NSC-10023” NCT00002565 ↗ |
| Known as | PDN | “This study compared the efficacy and safety of high-dose dexamethasone (HD-DXM) and conventional prednisone (PDN) on the largest cohort to date as first-line strategies for...” PMID 26480931 ↗ Oct 201511“Participants will be uniformly treated with four drug-induction: vincristine (VCR), prednisone (PDN), pegylated asparaginase (PegASP), daunorubicin (DNR).” NCT07443592 ↗ “Patients will be uniformly treated with four drug-induction: vincristine (VCR), prednisone (PDN), pegylated asparaginase (PegASP), daunorubicin (DNR).” NCT04179929 ↗ “Prednisone(PDN) is the standard corticosteroid therapy in ITP practical guideline usually given at 1 mg/kg per day for 4 weeks and then tapered.” NCT02914054 ↗ “Prednisone (PDN) on days 1-7 and one dose of methotrexate (MTX) intrathecal (IT) on day 1” NCT01117441 ↗ “Prednisone ( PDN ): 60 mg/m2 night , i.v. or p.o , 1-14 days” NCT02036489 ↗ “MPDN= methylprednisolone pulse PDN= prednisone or equivalent” NCT00323960 ↗ “Prednisone (PDN): 60 mg/m2/day, i.v. or p.o., days 1 to 14” NCT00526305 ↗ “Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27.” NCT02776605 ↗ “Prednisone (PDN): 60 mg/m2/d IV or PO, d 1-28” NCT00853008 ↗ “35 patients received prednisone (PDN) 40 mg/d” PMID 25945012 ↗ Apr 2015 “standard-dose prednisone [PDN]” PMID 38231017 ↗ Mar 2024 |
| Known as | PRED | “We conducted a prospective clinical trial testing nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) ± ipilimumab (IPI) in KTR with advanced cutaneous cancers.” PMID 38252910 ↗ Jan 202411“Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred” NCT04976465 ↗ “Cyclophosphamide (Cy) + Doxorubicin (ADM) + Vincristine (VDS) + Prednisone (Pred) ]± Rituximab (R)” NCT06520163 ↗ “Patients receive prednisone (PRED) on days 8-28.” NCT00613457 ↗ “oral prednisone (PRED) once daily on days 1-28” NCT00002514 ↗ “methylprednisolone (MP) or prednisone (pred)” NCT00657059 ↗ “Prednisone, PRED, NSC-10023” NCT00002462 ↗ “Prednisone, PRED, NSC-10023” NCT00002499 ↗ “PRED Prednisone, NSC-10023” NCT00002599 ↗ “PRED Prednisone, NSC-10023” NCT00002565 ↗ “PRED Prednisone, NSC-10023” NCT00002757 ↗ “Pred：prednisone” NCT03201471 ↗ |
| Known as | prednison | “standard CHOP chemotherapy (cyclophosphamide, 750mg per square meter of body-surface area,d1, vincristine, 1.4mg per square meter of body-surface area, maximal dose is 2mg d1,...” NCT02487316 ↗17“cyclophosphamide, anthracene nucleus chemotherapeutics（doxorubicin，liposomal doxorubicin, etc.）, vinca alkaloids（vincristine, vindesine, etc.），and glucocorticoid...” NCT05498259 ↗ “Continue Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician” NCT01958190 ↗ “Week 2-4 Prednison - 0,5-0,3 mg/kg/D Week 4-12 Prednison -0,3-0,2 mg/kg/D Month 4-6 Prednison 0,2 - 0,1 mg/kg/D Month 7 - Steroid withdrawal” NCT00195988 ↗ “Month 1: i.v. methylprednisolone (0.5 g) daily for three doses, then oral prednison (0.5 mg/kg/d, maximum dose 30mg/d) for 27 days” NCT04424862 ↗ “The CHOP include cyclophosphamide, doxorubicin/Epirubicin/liposomal doxorubicin, vincristine/Vindesine, and prednison.” NCT05933967 ↗ “Lenalidomide (Revlimid) in Combination With Cyclophosphamide (Endoxan) and Prednison (REP)” NCT01352338 ↗ “The R-CHOP include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednison.” NCT05234684 ↗ “etoposide 100mg/m2 days 1,2,3 Prednison 100 mg days 1,2,3,4,5 cycle repeated six times” NCT01502982 ↗ “Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w” NCT00991211 ↗ “Prednison: 100mg, po, d1-5” NCT07032532 ↗ “Prednison: 100mg, po, d1-5” NCT05238064 ↗ “Prednison：100mg/d，po，D1-5；” NCT02526823 ↗ |
| Known as | Prednisone (P) | “Prednisone (P)” NCT01858922 ↗ |
| Known as | Prednisone Acetate | “Oral prednisone acetate 1.5-2mg/kg/d (Max. 60mg/d) during methylprednisolone impact interval and later stage” NCT05969522 ↗11“oral prednisone (prednisone acetate, 0.3 mg/kg/day) is added to the above stable-stage regimen.” NCT07307534 ↗ “switch to oral prednisone acetate tablets after 5 days (calculated at 0.75 mg/kg/day)” NCT07546097 ↗ “prednisone acetate tablets (prednisone) 5 mg, once a day” NCT05376722 ↗ “Prednisone Acetate Tablets 1-1.5mg/kg/d d1-10 po” NCT04026269 ↗ |
| Known as | prednisone tablets | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02871869 ↗ |
| Known as | Steroids | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03192657 ↗ |
| Action | Inhibit | “According to it, we designed to inhibit the immune response at multi-targets with Prednisone Combined With MMF and FK506.” NCT00956059 ↗ |
| Modality | Other / unclassified | “corticosteroid treatment” NCT00000146 ↗ |
| Route | Oral | “Oral prednisone” NCT00000146 ↗ |
| Target | TNF | “TNF inhibition (prednisone)” NCT04497584 ↗ |